Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

15-year mortality 10 times higher among congenital heart surgery survivors

Although survival after congenital heart surgery is improving, patients who receive procedures for even mild defects have long-term mortality rates at least three times higher than their counterparts in the general population, according to a U.S.-based registry study published in the Journal of the American College of Cardiology.

Thumbnail

Acetaminophen may protect against acute kidney injury after pediatric heart surgery

Acetaminophen after pediatric heart surgery was associated with an increasingly protective effect against acute kidney injury (AKI), according to an analysis of separate cohorts at two children’s hospitals.

Transcatheter mitral chordal replacement system successful in 1st human patient

The first patient to be treated with a novel mitral valve repair system is recovering and showed no complications during a 30-day follow-up period, according to a press release issued by the system's developer.

Thumbnail

Edwards gains CE mark for first transcatheter tricuspid treatment

Edwards Lifesciences has received CE mark approval for its Cardioband Tricuspid Valve Reconstruction System, making it the first commercially available transcatheter therapy to treat tricuspid valve heart disease.

Thumbnail

Drug-related endocarditis leads to ethical dilemma for doctors

With the opioid epidemic in full swing and many intravenous drug users likely to relapse and require even more challenging and expensive treatment, physicians are left to grapple with what to do about repeat cases of infective endocarditis.

Thumbnail

Delayed discharge after TAVR linked to higher mortality

A late-breaking study presented at SCAI 2018 demonstrated that patients who stay in the hospital for more than 72 hours after transcatheter aortic valve replacement (TAVR) are more likely to die in the following year than those with earlier discharges.

Real-world MitraClip data show positive 1-year outcomes

A post-approval study of Abbott’s MitraClip device showed positive one-year results for the first 2,000 patients entered into the national Transcatheter Valve Therapy registry, according to late-breaking science presented April 26 at SCAI 2018 in San Diego.

Thumbnail

Researchers develop first tool to predict readmission rates after TAVR

The first-ever risk score for predicting 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR) can be easily folded into electronic medical records and inform perioperative care decisions, researchers reported at the Society for Cardiovascular Angiography and Interventions 2018 Scientific Sessions.

Displaying 849 - 856 of 874
Design by Adaptive Theme